NCT06608719View on ClinicalTrials.gov

Retrospective Study on the Safety and Therapeutic/Improvement Effects of Intravenous Administration of SHED-CM for ALS (SHED-CAH2023)

CompletedOBSERVATIONAL

Enrollment

24

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions

Amyotrophic Lateral Sclerosis

Interventions

BIOLOGICAL

The study drug is SHED-CM manufactured by U-Factor

Patients diagnosed with ALS were administered SHED-CM

Trial Locations (1)

102-0085

Hitonowa Medical, Chiyoda City

Sponsors

Lead Sponsor

Hitonowa Medical

All Listed Sponsors

lead

Hitonowa Medical

OTHER